S&P Futures
3,993.50 -26.25 (-0.65%) Dow Futures
31,959.00 -161.00 (-0.50%) Nasdaq Futures
12,286.75 -96.00 (-0.78%) Russell 2000 Futures
1,776.20 -13.30 (-0.74%) Crude Oil
109.40 -1.09 (-0.99%) Gold
1,803.50 -4.70 (-0.26%)
Rain Therapeutics Inc. (RAIN)
Chart Events
Performance Outlook
| Previous Close | 2.8600 |
| Open | 2.9400 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 800 |
| Day's Range | 2.5400 - 3.0267 |
| 52 Week Range | 2.5400 - 22.2200 |
| Volume | |
| Avg. Volume | 62,546 |
| Market Cap | 67.49M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8480 |
| Earnings Date | Nov 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.75 |
- GlobeNewswire
Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Progress
– Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 – – Phase 3 MANTRA topline data expected earlier than previously guided, now in first half of 2023, with enrollment anticipated to be completed by end of 2022 – – Phase 2 MANTRA-2 trial on-track with interim data anticipated in fourth quarter 2022 – – Based on enrollment progress from ongoing clinical studies, Phase 2 MANTRA-3 trial in Merkel cell carcinoma and Phase 1/2 MANTRA-4 basket trial for CDK
- GlobeNewswire
Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022
NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the first quarter ended March 31, 2022 and highlights of recent progress on Wednesday, May 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results. Conference Call and Webcast Deta
- Simply Wall St.
Rain Therapeutics Inc. (NASDAQ:RAIN) is up 11%, but insiders still continue to see a loss of US$1.6m on their US$2.2m investment
Insiders who bought US$2.2m worth of Rain Therapeutics Inc. ( NASDAQ:RAIN ) stock in the last year have seen some of...
